QNCX
Quince Therapeutics Inc

6,284
Mkt Cap
$193.77M
Volume
698,694.00
52W High
$4.55
52W Low
$0.7203
PE Ratio
-2.93
QNCX Fundamentals
Price
$3.57
Prev Close
$3.48
Open
$3.47
50D MA
$2.48
Beta
0.20
Avg. Volume
793,076.68
EPS (Annual)
-$1.31
P/B
183.74
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced that the...
Business Wire·5d ago
News Placeholder
More News
News Placeholder
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, announced the publication...
Business Wire·9d ago
News Placeholder
Monday Sector Laggards: Biotechnology, Electronic Equipment & Products
In trading on Monday, biotechnology shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of Quince Therapeutics, down about 16.2% and shares of Kalaris...
Nasdaq News: Markets·18d ago
News Placeholder
169,554 Shares in Quince Therapeutics, Inc. $QNCX Bought by Rockefeller Capital Management L.P.
Rockefeller Capital Management L.P. purchased a new stake in Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) in the second quarter, according to its most recent Form 13F filing with the...
MarketBeat·20d ago
News Placeholder
Quince Therapeutics to Participate at Investor Events in December 2025
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced that senior...
Business Wire·26d ago
News Placeholder
Brookline Capital Management Predicts QNCX FY2028 Earnings
Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) - Brookline Capital Management cut their FY2028 earnings estimates for shares of Quince Therapeutics in a report released on Thursday, November...
MarketBeat·1mo ago
News Placeholder
D. Boral Capital Reiterates "Buy" Rating for Quince Therapeutics (NASDAQ:QNCX)
D. Boral Capital reissued a "buy" rating and issued a $4.00 price target on shares of Quince Therapeutics in a research note on Thursday...
MarketBeat·1mo ago
News Placeholder
Quince Therapeutics (NASDAQ:QNCX) Announces Quarterly Earnings Results
Quince Therapeutics (NASDAQ:QNCX - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus...
MarketBeat·1mo ago
News Placeholder
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today provided an update on...
Business Wire·1mo ago
News Placeholder
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced the...
Business Wire·1mo ago
<
1
2
...
>

Latest QNCX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.